UroGen Pharma Is Maintained at Buy by D. Boral Capital

Dow JonesDec 6 07:25 ET · Ratings

UroGen Pharma Price Target Maintained With a $25.00/Share by D. Boral Capital

Dow JonesDec 6 07:25 ET · Ratings

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen PharmaDec 6 00:00 ET

UroGen Pharma Announces UGN-102 Long-Term Results In The Phase 3 ENVISION Trial, Potentially Paving The Way For First FDA-Approved Treatment For LG-IR-NMIBC; UGN-102 Demonstrated 82.3% Duration Of Response At 12 Months In Patients Who Achieved...

BenzingaDec 5 15:18 ET

UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC

UroGen PharmaDec 5 00:00 ET

UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs

UroGen PharmaDec 2 00:00 ET